| First Author | Bourgeois C | Year | 1998 |
| Journal | J Virol | Volume | 72 |
| Issue | 1 | Pages | 807-10 |
| PubMed ID | 9420291 | Mgi Jnum | J:44979 |
| Mgi Id | MGI:1101557 | Doi | 10.1128/jvi.72.1.807-810.1998 |
| Citation | Bourgeois C, et al. (1998) Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice. J Virol 72(1):807-10 |
| abstractText | Immunotherapy with antibodies against respiratory syncytial virus (RSV) is a treatment option given the absence of any vaccine or other available satisfactory treatment. We selected one of our monoclonal antibodies, RS-348, that is highly neutralizing. We showed that a single peptide (PEP3H) derived from complementarity-determining region 3 (CDR3) of its heavy chain was capable of neutralizing the virus in vitro. When intranasally administered 24 h before challenge, this peptide protected BALB/c mice against RSV lung infection. These results indicate that a single CDR can be effective against RSV infection. |
